Report cover image

Substance Abuse Treatment Market (Treatment Type: Drug Abuse Treatment, Nicotine Addiction Treatment, and Alcohol Addiction) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Publisher Transparency Market Research Pvt. Ltd.
Published Jul 06, 2022
Length 445 Pages
SKU # TNPR17372923

Description

Substance Abuse Treatment Market (Treatment Type: Drug Abuse Treatment, Nicotine Addiction Treatment, and Alcohol Addiction) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Substance Abuse Treatment Market – Scope of Report
TMR’s report on the global substance abuse treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global substance abuse treatment market for the period 2017–2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global substance abuse treatment market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the substance abuse treatment market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global substance abuse treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global substance abuse treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global substance abuse treatment market.

The report delves into the competitive landscape of the global substance abuse treatment market. Key players operating in the global substance abuse treatment market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global substance abuse treatment market profiled in this report.

RESEARCH METHODOLOGY

The research methodology will be a combination of exhaustive primary and secondary research to analyze the market substance abuse treatment.

Secondary Research

Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.

Secondary research sources that we typically refer, but are not limited to:

Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market

Specific Secondary Sources:

Industry Sources:
WorldWideScience.org
Elsevier, Inc.
National Institutes of Health (NIH)
PubMed
NCBI
Department of Health Care Service
Trade Data Sources
Trade Map
UN Comtrade
Trade Atlas
Company Information
OneSource Business Browser
Hoover’s
Factiva
Bloomberg
Mergers & Acquisitions
Thomson Mergers & Acquisitions
MergerStat
Profound

Primary Research

During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.

We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:

Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies

Participants who typically take part in such a process include, but are not limited to:

Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals

List of primary participants, but not limited to:

Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.

Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.

Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:

Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities

Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.

Table of Contents

445 Pages
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Substance Abuse Treatment Market
4. Market Overview
4.1. Introduction
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Substance Abuse Treatment Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Pipeline Analysis
5.2. Porter’s Five Force Analysis
5.3. Value Chain Analysis
5.4. Key Industry Development
5.5. Top Company’s Product Specification Details
6. Global Substance Abuse Treatment Market Analysis and Forecast, by Treatment Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Treatment Type, 2017–2031
6.3.1. Alcohol Addiction
6.3.1.1. Disulfiram
6.3.1.2. Acamprosate
6.3.1.3. Naltrexone
6.3.1.4. Others
6.3.2. Nicotine Addiction
6.3.2.1. Total NRT Therapy
6.3.2.2. Varenicline
6.3.2.3. Bupropion
6.3.3. Drug Abuse Treatment
6.3.3.1. Methadone
6.3.3.2. Buprenorphine
6.3.3.3. Naltexone
6.4. Market Attractiveness Analysis, by Treatment Type
7. Global Substance Abuse Treatment Market Analysis and Forecast, by Distribution Channel Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Distribution Channel, 2017–2031
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies & Drug Stores
7.3.3. Others (online sales)
7.4. Market Attractiveness Analysis, by Distribution Channel
8. Global Substance Abuse Treatment Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Region
9. North America Substance Abuse Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Treatment Type, 2017–2031
9.2.1. Alcohol Addiction
9.2.1.1. Disulfiram
9.2.1.2. Acamprosate
9.2.1.3. Naltrexone
9.2.1.4. Others
9.2.2. Nicotine Addiction
9.2.2.1. Total NRT Therapy
9.2.2.2. Varenicline
9.2.2.3. Bupropion
9.2.3. Drug Abuse Treatment
9.2.3.1. Methadone
9.2.3.2. Buprenorphine
9.2.3.3. Naltexone
9.3. Market Value Forecast, by Distribution Channel, 2017–2031
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies & Drug Stores
9.3.3. Others (online sales)
9.3.4. Market Value Forecast, by Distribution Channel, 2017–2031
9.3.5. Hospital Pharmacies
9.3.6. Retail Pharmacies & Drug Stores
9.3.7. Others (online sales)
9.4. Market Value Forecast, by Country, 2017–2031
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Treatment Type
9.5.2. By Distribution Channel Type
9.5.3. By Country
10. Europe Substance Abuse Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Treatment Type, 2017–2031
10.2.1. Alcohol Addiction
10.2.1.1. Disulfiram
10.2.1.2. Acamprosate
10.2.1.3. Naltrexone
10.2.1.4. Others
10.2.2. Nicotine Addiction
10.2.2.1. Total NRT Therapy
10.2.2.2. Varenicline
10.2.2.3. Bupropion
10.2.3. Drug Abuse Treatment
10.2.3.1. Methadone
10.2.3.2. Buprenorphine
10.2.3.3. Naltexone
10.3. Market Value Forecast, by Distribution Channel, 2017–2031
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies & Drug Stores
10.3.3. Others (online sales)
10.3.4. Market Value Forecast, by Distribution Channel, 2017–2031
10.4. Market Value Forecast, by Country/Sub-region, 2017–2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Treatment Type
10.5.2. By Distribution Channel Type
10.5.3. By Country/Sub-region
11. Asia Pacific Substance Abuse Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Treatment Type, 2017–2031
11.2.1. Alcohol Addiction
11.2.1.1. Disulfiram
11.2.1.2. Acamprosate
11.2.1.3. Naltrexone
11.2.1.4. Others
11.2.2. Nicotine Addiction
11.2.2.1. Total NRT Therapy
11.2.2.2. Varenicline
11.2.2.3. Bupropion
11.2.3. Drug Abuse Treatment
11.2.3.1. Methadone
11.2.3.2. Buprenorphine
11.2.3.3. Naltexone
11.3. Market Value Forecast, by Distribution Channel, 2017–2031
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies & Drug Stores
11.3.3. Others (online sales)
11.4. Market Value Forecast, by Country/Sub-region, 2017–2031
11.4.1. Japan
11.4.2. China
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of APAC
11.5. Market Attractiveness Analysis
11.5.1. By Treatment Type
11.5.2. By Distribution Channel Type
11.5.3. By Country/Sub-region
12. Latin America Substance Abuse Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Treatment Type, 2017–2031
12.2.1. Alcohol Addiction
12.2.1.1. Disulfiram
12.2.1.2. Acamprosate
12.2.1.3. Naltrexone
12.2.1.4. Others
12.2.2. Nicotine Addiction
12.2.2.1. Total NRT Therapy
12.2.2.2. Varenicline
12.2.2.3. Bupropion
12.2.3. Drug Abuse Treatment
12.2.3.1. Methadone
12.2.3.2. Buprenorphine
12.2.3.3. Naltexone
12.3. Market Value Forecast, by Distribution Channel, 2017–2031
12.3.1. Hospital Pharmacies
12.3.2. Retail Pharmacies & Drug Stores
12.3.3. Others (online sales)
12.4. Market Value Forecast, by Country/Sub-region, 2017–2031
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of LATAM
12.5. Market Attractiveness Analysis
12.5.1. By Treatment Type
12.5.2. By Distribution Channel Type
12.5.3. By Country/Sub-region
13. Middle East & Africa Substance Abuse Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Treatment Type, 2017–2031
13.2.1. Alcohol Addiction
13.2.1.1. Disulfiram
13.2.1.2. Acamprosate
13.2.1.3. Naltrexone
13.2.1.4. Others
13.2.2. Nicotine Addiction
13.2.2.1. Total NRT Therapy
13.2.2.2. Varenicline
13.2.2.3. Bupropion
13.2.3. Drug Abuse Treatment
13.2.3.1. Methadone
13.2.3.2. Buprenorphine
13.2.3.3. Naltexone
13.3. Market Value Forecast, by Distribution Channel, 2017–2031
13.3.1. Hospital Pharmacies
13.3.2. Retail Pharmacies & Drug Stores
13.3.3. Others (online sales)
13.4. Market Value Forecast, by Country/Sub-region, 2017–2031
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of MEA
13.5. Market Attractiveness Analysis
13.5.1. By Treatment Type
13.5.2. By Distribution Channel Type
13.5.3. By Country/Sub-region
14. Competitive Landscape
14.1. Market Player - Competition Matrix (by tier and size of companies)
14.2. Market Share Analysis, by Company, 2021
14.3. Company Profiles
14.3.1. Alkermes
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Company Financials
14.3.1.3. Growth Strategies
14.3.1.4. SWOT Analysis
14.3.2. Allergan plc
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Company Financials
14.3.2.3. Growth Strategies
14.3.2.4. SWOT Analysis
14.3.3. Indivior plc
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Company Financials
14.3.3.3. Growth Strategies
14.3.3.4. SWOT Analysis
14.3.4. Noramco (part of SK Capital Partners)
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Company Financials
14.3.4.3. Growth Strategies
14.3.4.4. SWOT Analysis
14.3.5. Teva Pharmaceutical Industries Ltd.
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Company Financials
14.3.5.3. Growth Strategies
14.3.5.4. SWOT Analysis
14.3.6. Pfizer, Inc.
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Company Financials
14.3.6.3. Growth Strategies
14.3.6.4. SWOT Analysis
14.3.7. GlaxoSmithKline plc
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Company Financials
14.3.7.3. Growth Strategies
14.3.7.4. SWOT Analysis
14.3.8. Mallinckrodt plc
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Company Financials
14.3.8.3. Growth Strategies
14.3.8.4. SWOT Analysis
14.3.9. BioCorRx, Inc.
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Company Financials
14.3.9.3. Growth Strategies
14.3.9.4. SWOT Analysis
14.3.10. Glenmark Pharmaceuticals Ltd.
14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.10.2. Company Financials
14.3.10.3. Growth Strategies
14.3.10.4. SWOT Analysis

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us